Telomir Pharmaceuticals (NASDAQ: TELO) has published peer-reviewed preclinical data in Advances in Redox Research demonstrating that its investigational drug Telomir-Zn provided dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The findings, announced in a press release, include reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, supporting the biological activity of Telomir-Zn in Wilson’s disease.
Wilson’s disease is a rare genetic disorder characterized by copper accumulation in tissues, primarily the liver and brain, leading to progressive damage. Current treatments include chelation therapy and zinc supplementation, but many patients experience inadequate response or side effects. Telomir-Zn’s mechanism targets intracellular metal homeostasis and redox balance, which may offer a novel approach.
The preclinical study expands the scientific validation of Telomir-Zn as the company advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation. According to the company, Telomir-Zn has also demonstrated activity in modulating epigenetically regulated gene expression, mitochondrial function, and genomic stability in preclinical studies.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics focused on fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), is being investigated for multiple indications.
Investors can find the latest news and updates relating to TELO in the company’s newsroom at https://ibn.fm/TELO.
For more information on Telomir Pharmaceuticals, visit their website. The full press release is available at https://ibn.fm/fOSNo.
